Methodologic aspects of a standardized evaluation of mitotic activity in tumor tissues;Methodische aspekte bei der standardisierten beurteilung der mitotischen aktivitat von tumorgeweben

Pathologe

Volumn 18, Issue 6, 1997, Pages 439-444

  Biesterfeld, S ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Diagnosis; Mitotis; Pathology; Prognosis; Reliability; Standardization; Tumor

Indexed keywords

CANCER GRADING; HISTOPATHOLOGY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MITOSIS RATE; MORPHOMETRICS; REPRODUCIBILITY; REVIEW; STANDARDIZATION; TUMOR CELL;

HUMANS; MITOSIS; MITOTIC INDEX; NEOPLASMS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 0031469318     PISSN: 01728113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002920050239     Document Type: Review

References (37)

1. Aaltomaa S, Lipponen P, Syrjänen K (1993) Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res 13:533-538
2. Baak JPA (1990) Mitosis counting in tumors. Hum Pathol 21:683-685
3. Baak JPA, van Dop H, Kurver PHJ, Hermans J (1985) The value of morphometry to classic prognosticators in breast cancer. Cancer 56:374-382
4. Biesterfeld S, Klüppel D, Koch R, Schneider S, Steinhagen G, Mihalcea AM (im Druck) Rapid and prognostically valid quantification of immunohistochemical reactions by immunohistometry of the most positive tumor focus. A prospective follow-up study on breast cancer using antibodies against MIB-1, PCNA, ER and PR. J Pathol
5. Biesterfeld S, Noll I, Noll E, Wohltmann D, Böcking A (1995) Mitotic frequency as a prognostic factor in breast cancer. Hum Pathol 26:47-52
6. Bloom HJG, Richardson WH (1957) Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377
7. Cavanagh JB, Lewis PD (1969) Perfusion-fixation, colchicine and mitotic activity in the adult rat brain. J Anat 104:341-350
8. Collan YUI, Kuopio T, Baak JPA, Becker R, Bogomoletz WV, Deverell M, van Diest P, van Galen C, Gilchrist K, Javed A, Kosma VM, Jujari H, Luzi P, Mariuzzi GM, Matze E, Montironi R, Scarpelli M, Sierra D, Sisti S, Toikkanen S, Tosi P, Whimster WF, Wisse E (1996) Standardizied mitotic counts in breast cancer. Evaluation of the method. Pathol Res Pract 192:931-941
9. Delahunt B, Bethwaite PB, Nacey JN, Ribas JL (1993) Proliferating cell nuclear antigen (PCNA) expression as a prognostic indicator for renal cell carcinoma: comparison with tumour grade, mitotic index, and silver staining nucleolar organizer region numbers. J Pathol 170:471-477
10. van Diest PJ, Baak JPA, Matze-Cok P, Wisse-Brekelmans ECM, van Galen CM, Kurver PHJ, Bellot SM, Fijnheer J, van Gorp LHM, Kwee WS, Los J, Peterse JL, Ruitenberg HM, Schapers RFM, Schipper MEI, Somsen JG, Willig AWPM, Ariens AT (1992) Reproducibility of mitosis counting in 2,469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum Pathol 23:603-607
11. Donhuijsen K, Schmidt U, Hirche H, van Beuningen D, Budach V (1990) Changes in mitotic rate and cell cycle fractions by delayed fixation. Hum Pathol 21:709-714
12. Eccles BA, Klevecz RR (1986) Automatic digital image analysis for identification of mitotic cells in synchronous mammalian cell cultures. Anal Quant Cytol Histol 8:138-147
13. Ellis PSJ, Whitehead R (1981) Mitosis counting - a need for reappraisal. Hum Pathol 12:3-4
14. Enzinger FM, Smith BH (1976) Hemangiopericytoma. An analysis of 106 cases. Hum Pathol 7:61-82
15. Graem M, Helweg-Laersen K (1979) Mitotic activity and delay in fixation in tumour tissue. Acta Pathol Microbiol Scand A 87:375-378
16. Hendrickson MR, Kempson RL (1989) The uterine corpus. In: Sternberg SS (ed) Diagnostic surgical pathology, vol 2, chap 48. pp 1635-1647
17. Isola JJ, Helin HJ, Helle MJ, Kallioniemi OP (1990) Evaluation of cell proliferation in breast carcinoma. Comparison of Ki-67 immunohistochemical study, DNA flow cytometric analysis, and mitotic count. Cancer 65:1180-1184
18. Jain S, Filipe Ml, Hall PA, Waseem N, Lane DP, Levison DA (1991) Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol 44:655-659
19. Kaman EJ, Smeulders AW, Verbeek PW, Young TT, Baak JP (1984) Image processing for mitoses in sections of breast cancer: a feasibility study. Cytometry 5:244-249
20. ten Kate TK, Relien JA, Smeulders AW, Baak JP (1993) Method for counting mitoses by image processing in Feulgen stained breast cancer sections. Cytometry 14:241-250
21. Kawai T, Suzuki M, Kono S, Shinomiya N, Rokutanda M, Takagi K, Ogata T, Tamai S (1994) Proliferating cell nuclear antigen and Ki67 in lung carcinoma.Correlation with DNA flow cytometric analysis. Cancer 74:2468-2475
22. Kempson RL, Bari W (1970) Uterine sarcomas. Classification, diagnosis and prognosis. Hum Pathol 1:331-349
23. Keshgegian AA, Cnaan A (1995) Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol 104:42-49
24. Myhre Jensen O, Kaae S, Madsen SH, Sneppen O (1983) Histopathological grading in soft tissue tumours. Relation to survival in 261 surgically treated patients. Acta Pathol Microbiol Scand A 91:145-150
25. Nakano T, Oka K (1993) Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 72:2401-2408
26. Noll I (1992) Prognostische Validität, Reproduzierbarkeit und Repräsentativität der Mitosezahl beim Mammakarzinom im Vergleich zu anderen Gradierungen. Med Diss, RWTH Aachen
27. O'Leary TJ, Steffes MW (1996) Can you count on the mitotic index? Hum Pathol 27:147-151
28. Patey DH, Scarff RW (1928) The position of histology in the prognosis of carcinoma of the breast. Lancet 1:808
29. Pich A, Ponti R, Valente G, Chiusa L, Geuna M, Novero D, Palestro G (1994) MIB-1, Ki67, and PCNA scores and DNA flow cytometry in intermediate grade malignant lymphomas. J Clin Pathol 47:18-22
30. Railo M, Nordling S, von Boguslawsky K, Leivonen M, Kyllonen L, Smitten K (1993) Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 68:579-583
31. Ramael M, Jacobs W, Weyler J, van Meerbeck J, Bialasiewicz P, van den Bossche J, Buysse C, Vermeire P, van Marck E (1994) Proliferation in malignant mesothelioma as determined by mitosis counts and immunoreactivity for proliferating cell nuclear antigen (PCNA). J Pathol 172:247-253
32. Ruijter DJ, van Rijssel TG, van der Velde EA (1977) Aneurysmal bone cyst. A clinicopathological study of 105 cases. Cancer 39:2231-2239
33. Sallinen PK, Haapasalo HK, Visakorpi T, Helen PT, Rantalal S, Isola JJ, Helin HJ (1994) Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples. J Pathol 174:275-282
34. Schröder R, Ploner C, Ernestus RI (1993) The growth potential of ependymomas with varying grades of malignancy measured by the Ki-67 labelling index and mitotic index. Neurosurg Rev 16:145-150
35. Scotlandi K, Serra M, Manara MC, Maurici D, Benini S, Mini G, Companacci M, Baldini N (1995) Clinical relevance of Ki-67 expression in bone tumors. Cancer 75:806-814
36. Taagepara S, Rao PN, Drake FH, Gorbsky GJ (1993) DNA topoisomerase IIα is the major chromosome protein recognized by the mitotic phosphoprotein antibody MPM-2. Cell Biology 90:8407-8411
37. Yonemura Y, Kimura H, Fushida S, Tugawa K, Nakai Y, Kaji M, Fonseca L, Yamaguchi A, Miyazaki I (1993) Analysis of proliferative activity using anti-proliferating cell nuclear antigen antibody in gastric cancer tissue specimens obtained by endoscopic biopsy. Cancer 71:2448-2453